{
  "pack": {
    "name": "ASCO GI 2026",
    "tagline": "Pharma sponsors and presenting authors at the 2026 ASCO GI Symposium",
    "description": "50 pharma and biotech companies with sponsored abstracts at ASCO GI 2026 (January 23-25, San Francisco). Includes verified presenting authors — the oncology leaders driving GI cancer programs.",
    "targetBuyer": "Oncology-focused platforms, clinical trial software, medical affairs tools, RWE vendors",
    "price": 500,
    "refreshCadence": "Monthly",
    "lastUpdated": "2026-02-03",
    "totalCompanies": 50,
    "totalStakeholders": 150,
    "stakeholdersLocked": true
  },
  "companies": [
    {
      "rank": 1,
      "company": "AstraZeneca",
      "domain": "astrazeneca.com",
      "abstractCount": 13,
      "signalDetail": "13 sponsored abstracts at ASCO GI 2026 (1 oral, 12 poster). Lead: \"ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment ...\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Manish A. Shah",
          "Diogo B. Gomes",
          "Kohei Shitara"
        ],
        "people": [
          {
            "name": "Manish A. Shah",
            "title": "Professor of Medicine, Weill Cornell Medical College",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Manish%20A.%20Shah",
            "company": "AstraZeneca"
          },
          {
            "name": "Diogo B. Gomes",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Diogo%20B.%20Gomes",
            "company": "AstraZeneca"
          },
          {
            "name": "Kohei Shitara",
            "title": "Chief, Department of GI Oncology, National Cancer Center Hospital East",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Kohei%20Shitara",
            "company": "AstraZeneca"
          },
          {
            "name": "Yelena Y. Janjigian",
            "title": "Chief, GI Oncology, Memorial Sloan Kettering",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Yelena%20Y.%20Janjigian",
            "company": "AstraZeneca"
          }
        ]
      }
    },
    {
      "rank": 2,
      "company": "Astellas Pharma Inc.",
      "domain": "astellas.com",
      "abstractCount": 6,
      "signalDetail": "6 sponsored abstracts at ASCO GI 2026 (1 oral, 5 poster). Lead: \"Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2+ locally advanced (LA) unresectable or metastatic gastr...\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Kohei Shitara",
          "Hirokazu Shoji",
          "Peter C. Enzinger"
        ],
        "people": [
          {
            "name": "Kohei Shitara",
            "title": "Chief, Department of GI Oncology, National Cancer Center Hospital East",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Kohei%20Shitara",
            "company": "Astellas Pharma Inc."
          },
          {
            "name": "Hirokazu Shoji",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Hirokazu%20Shoji",
            "company": "Astellas Pharma Inc."
          },
          {
            "name": "Peter C. Enzinger",
            "title": "Director, Esophageal Cancer Center, Dana-Farber",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Peter%20C.%20Enzinger",
            "company": "Astellas Pharma Inc."
          },
          {
            "name": "Rupali Fuldeore",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Rupali%20Fuldeore",
            "company": "Astellas Pharma Inc."
          }
        ]
      }
    },
    {
      "rank": 3,
      "company": "Pfizer",
      "domain": "pfizer.com",
      "abstractCount": 4,
      "signalDetail": "4 sponsored abstracts at ASCO GI 2026 (1 oral, 3 poster). Lead: \"RIVER-mPDAC: A phase 2b/3 study of ponsegromab for the treatment of cachexia in patients with metastatic pancreatic ductal adenocarcinoma receiving fi...\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Eric Roeland",
          "Imran Y. Ali",
          "Vanessa Wookey"
        ],
        "people": [
          {
            "name": "Eric Roeland",
            "title": "Associate Professor, Supportive Care Medicine, OHSU",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Eric%20Roeland",
            "company": "Pfizer"
          },
          {
            "name": "Imran Y. Ali",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Imran%20Y.%20Ali",
            "company": "Pfizer"
          },
          {
            "name": "Vanessa Wookey",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Vanessa%20Wookey",
            "company": "Pfizer"
          },
          {
            "name": "Anush Narasimhan Sridharan",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Anush%20Narasimhan%20Sridharan",
            "company": "Pfizer"
          }
        ]
      }
    },
    {
      "rank": 4,
      "company": "Bristol Myers Squibb",
      "domain": "bms.com",
      "abstractCount": 4,
      "signalDetail": "4 sponsored abstracts at ASCO GI 2026 (1 oral, 3 poster). Lead: \"A phase 2/3 randomized study of BMS-986504 with nab-paclitaxel (nab-P) and gemcitabine (GEM) in first-line (1L) metastatic pancreatic ductal adenocarc...\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Shubham Pant",
          "Michel P. Ducreux",
          "Reginald Villacorta"
        ],
        "people": [
          {
            "name": "Shubham Pant",
            "title": "Professor, GI Medical Oncology, MD Anderson",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Shubham%20Pant",
            "company": "Bristol Myers Squibb"
          },
          {
            "name": "Michel P. Ducreux",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Michel%20P.%20Ducreux",
            "company": "Bristol Myers Squibb"
          },
          {
            "name": "Reginald Villacorta",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Reginald%20Villacorta",
            "company": "Bristol Myers Squibb"
          },
          {
            "name": "Ijeoma Oyetunde",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Ijeoma%20Oyetunde",
            "company": "Bristol Myers Squibb"
          }
        ]
      }
    },
    {
      "rank": 5,
      "company": "Servier",
      "domain": "servier.com",
      "abstractCount": 3,
      "signalDetail": "3 sponsored abstracts at ASCO GI 2026 (1 oral, 2 poster). Lead: \"A phase 1/2, open-label study of oral S241656 (BDTX-4933) as monotherapy and in combination with other anti-cancer therapies in patients with KRAS, BR...\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Ajay Prakash",
          "Michael Offin",
          "Denice Kamp"
        ],
        "people": [
          {
            "name": "Ajay Prakash",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Ajay%20Prakash",
            "company": "Servier"
          },
          {
            "name": "Michael Offin",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Michael%20Offin",
            "company": "Servier"
          },
          {
            "name": "Denice Kamp",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Denice%20Kamp",
            "company": "Servier"
          },
          {
            "name": "Merel van Velzen",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Merel%20van%20Velzen",
            "company": "Servier"
          }
        ]
      }
    },
    {
      "rank": 6,
      "company": "Incyte Corporation",
      "domain": null,
      "abstractCount": 3,
      "signalDetail": "3 sponsored abstracts at ASCO GI 2026 (1 oral, 2 poster). Lead: \"Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy ...\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Zev A. Wainberg",
          "Jason T. Henry",
          "Sumit Verma"
        ],
        "people": [
          {
            "name": "Zev A. Wainberg",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Zev%20A.%20Wainberg",
            "company": "Incyte Corporation"
          },
          {
            "name": "Jason T. Henry",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Jason%20T.%20Henry",
            "company": "Incyte Corporation"
          },
          {
            "name": "Sumit Verma",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Sumit%20Verma",
            "company": "Incyte Corporation"
          },
          {
            "name": "Shreekant Parasuraman",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Shreekant%20Parasuraman",
            "company": "Incyte Corporation"
          }
        ]
      }
    },
    {
      "rank": 7,
      "company": "Boehringer Ingelheim",
      "domain": null,
      "abstractCount": 3,
      "signalDetail": "3 sponsored abstracts at ASCO GI 2026 (3 poster). Lead: \"Obrixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (...\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Marianne Pavel",
          "Chris Verslype",
          "Paul E. Oberstein"
        ],
        "people": [
          {
            "name": "Marianne Pavel",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Marianne%20Pavel",
            "company": "Boehringer Ingelheim"
          },
          {
            "name": "Chris Verslype",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Chris%20Verslype",
            "company": "Boehringer Ingelheim"
          },
          {
            "name": "Paul E. Oberstein",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Paul%20E.%20Oberstein",
            "company": "Boehringer Ingelheim"
          },
          {
            "name": "Drew W. Rasco",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Drew%20W.%20Rasco",
            "company": "Boehringer Ingelheim"
          }
        ]
      }
    },
    {
      "rank": 8,
      "company": "Ipsen",
      "domain": null,
      "abstractCount": 3,
      "signalDetail": "3 sponsored abstracts at ASCO GI 2026 (3 poster). Lead: \"Phase II study of NALIRIFOX (nanoliposomal irinotecan + oxaliplatin with fluorouracil and folinic acid) in advanced unresectable small bowel tumors....\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Tiago Biachi de Castria",
          "Angela T. Alistar",
          "Vincent J. Picozzi"
        ],
        "people": [
          {
            "name": "Tiago Biachi de Castria",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Tiago%20Biachi%20de%20Castria",
            "company": "Ipsen"
          },
          {
            "name": "Angela T. Alistar",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Angela%20T.%20Alistar",
            "company": "Ipsen"
          },
          {
            "name": "Vincent J. Picozzi",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Vincent%20J.%20Picozzi",
            "company": "Ipsen"
          },
          {
            "name": "Mannat Sukhija",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Mannat%20Sukhija",
            "company": "Ipsen"
          }
        ]
      }
    },
    {
      "rank": 9,
      "company": "Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA",
      "domain": "merck.com",
      "abstractCount": 3,
      "signalDetail": "3 sponsored abstracts at ASCO GI 2026 (3 poster). Lead: \"Descriptive analysis of outcomes in participants with combined hepatocellular-cholangiocarcinoma in the phase 3 KEYNOTE-966 trial....\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Julien Edeline",
          "Elia Gigante",
          "Thierry Andre"
        ],
        "people": [
          {
            "name": "Julien Edeline",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Julien%20Edeline",
            "company": "Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"
          },
          {
            "name": "Elia Gigante",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Elia%20Gigante",
            "company": "Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"
          },
          {
            "name": "Thierry Andre",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Thierry%20Andre",
            "company": "Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"
          },
          {
            "name": "Filippo Pietrantonio",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Filippo%20Pietrantonio",
            "company": "Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"
          }
        ]
      }
    },
    {
      "rank": 10,
      "company": "GSK",
      "domain": null,
      "abstractCount": 3,
      "signalDetail": "3 sponsored abstracts at ASCO GI 2026 (3 poster). Lead: \"Real-world patient-reported outcomes in stage II/III rectal cancer in the Netherlands....\"",
      "stakeholders": {
        "count": 4,
        "locked": false,
        "preview": [
          "Renee A. Lunenberg",
          "Frederieke H. van der Baan",
          "Jeanine Roodhart"
        ],
        "people": [
          {
            "name": "Renee A. Lunenberg",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Renee%20A.%20Lunenberg",
            "company": "GSK"
          },
          {
            "name": "Frederieke H. van der Baan",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Frederieke%20H.%20van%20der%20Baan",
            "company": "GSK"
          },
          {
            "name": "Jeanine Roodhart",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Jeanine%20Roodhart",
            "company": "GSK"
          },
          {
            "name": "Sean O’Donnell",
            "title": "Presenting Author, ASCO GI 2026",
            "linkedin": "https://linkedin.com/search/results/people/?keywords=Sean%20O%E2%80%99Donnell",
            "company": "GSK"
          }
        ]
      }
    },
    {
      "rank": 11,
      "company": "U.S. National Institutes of Health",
      "domain": null,
      "abstractCount": 3,
      "signalDetail": "3 sponsored abstracts at ASCO GI 2026 (1 oral, 2 poster). Lead: \"Physical activity and molecular residual disease (MRD) in stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702....\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "George Q. Zhang",
          "Chao Ma",
          "Christopher Lieu"
        ],
        "people": []
      }
    },
    {
      "rank": 12,
      "company": "Jazz Pharmaceuticals",
      "domain": "jazzpharma.com",
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (1 oral, 1 poster). Lead: \"Zanidatamab (zani) + chemotherapy (chemo) ± tislelizumab (tisle) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenoc...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Elena Elimova",
          "Sun Young Rha",
          "James J. Harding"
        ],
        "people": []
      }
    },
    {
      "rank": 13,
      "company": "MSD",
      "domain": "merck.com",
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"An open label phase 2 study of total neoadjuvant therapy (TNT) consisting of FLOT with pembrolizumab and short radiation for patients with locally adv...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Kazuma Sato",
          "Izuma Nakayama",
          "Choong-kun Lee"
        ],
        "people": []
      }
    },
    {
      "rank": 14,
      "company": "UCI Health Chao Family Comprehensive Cancer Center",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Response adapted neoadjuvant therapy in gastric cancer (RANT-GC): A phase Ib feasibility trial....\"",
      "stakeholders": {
        "count": 3,
        "locked": true,
        "preview": [
          "Farshid Dayyani",
          "April Choi",
          "Jennifer B. Valerin"
        ],
        "people": []
      }
    },
    {
      "rank": 15,
      "company": "Shanghai Henlius Biotech, Inc.",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"A randomized, double-blinded, international phase III trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and ch...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Jaffer A. Ajani",
          "Ken Kato",
          "Linlin Wang"
        ],
        "people": []
      }
    },
    {
      "rank": 16,
      "company": "BeOne Medicines, Ltd",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (1 oral, 1 poster). Lead: \"Treatment patterns in advanced gastric cancer (GC) across racial and ethnic groups in the immunotherapy era: A retrospective claims data analysis in t...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "A. C. Lockhart",
          "Bassel F. El-Rayes",
          "Marcia R. Cruz-Correa"
        ],
        "people": []
      }
    },
    {
      "rank": 17,
      "company": "Astellas Pharma, Inc.",
      "domain": "astellas.com",
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Assessment of the impact of proton pump inhibitor (PPI) exposure on survival outcomes in patients with gastric or gastroesophageal junction adenocarci...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Akihiro Yamada",
          "Jianning Yang",
          "Guoqiang Zhang"
        ],
        "people": []
      }
    },
    {
      "rank": 18,
      "company": "Astellas",
      "domain": "astellas.com",
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Safety run-in results from C-SOLVE (JACCRO GC-12): A randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in patients with HE...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Hisato Kawakami",
          "Satoshi Yuki",
          "Anup Kasi"
        ],
        "people": []
      }
    },
    {
      "rank": 19,
      "company": "Natera",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Tumor-informed ctDNA monitoring during surveillance for early detection of recurrence in patients with stage II/III esophageal cancer treated with che...\"",
      "stakeholders": {
        "count": 3,
        "locked": true,
        "preview": [
          "Sahar Forootan Sedigh",
          "Ani Antaramian",
          "David Russo"
        ],
        "people": []
      }
    },
    {
      "rank": 20,
      "company": "RayzeBio",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"A phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) in patients with glypican-3-positive (GPC3+) previously treate...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Brandon R. Mancini",
          "Medhat Osman",
          "Heloisa P. Soares"
        ],
        "people": []
      }
    },
    {
      "rank": 21,
      "company": "Exact Sciences Corporation",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Inferring liver cancer stage from Medicare claims data: A machine learning approach to broaden outcomes research....\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Rebecca Smith",
          "Xiting Cao"
        ],
        "people": []
      }
    },
    {
      "rank": 22,
      "company": "Genentech, a member of the Roche Group",
      "domain": "gene.com",
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Enhancing personalized, evidence-based care for veterans with hepatocellular carcinoma (HCC): Insights from a team-based quality improvement initiativ...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Bhaumik Patel",
          "Ilona Dewald",
          "Richard S. Finn"
        ],
        "people": []
      }
    },
    {
      "rank": 23,
      "company": "Novartis Pharmaceuticals Corporation",
      "domain": "novartis.com",
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Retreatment patterns and outcomes in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with [<sup>177</sup>Lu]Lu-DOT...\"",
      "stakeholders": {
        "count": 3,
        "locked": true,
        "preview": [
          "Aman Chauhan",
          "Samuel Crawford",
          "Heloisa P. Soares"
        ],
        "people": []
      }
    },
    {
      "rank": 24,
      "company": "Alpha Tau Medical",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Feasibility, safety and efficacy of endoscopic ultrasound-guided alpha radiotherapy for advanced pancreatic cancer: A pilot study....\"",
      "stakeholders": {
        "count": 3,
        "locked": true,
        "preview": [
          "Corey Miller",
          "Kim A. Ma",
          "Nissim Benizri"
        ],
        "people": []
      }
    },
    {
      "rank": 25,
      "company": "F. Hoffmann-La Roche Ltd",
      "domain": "roche.com",
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) tria...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Jaume Capdevila",
          "David Paez",
          "Marwan Fakih"
        ],
        "people": []
      }
    },
    {
      "rank": 26,
      "company": "Freenome Holdings, Inc.",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Clinical performance of an improved colorectal cancer (CRC) screening blood test....\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Aasma Shaukat",
          "Alexander F. Lovejoy",
          "Chung-Kai Sun"
        ],
        "people": []
      }
    },
    {
      "rank": 27,
      "company": "Takeda Pharmaceuticals U.S.A., Inc, Cambridge, MA, USA",
      "domain": "takeda.com",
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Number needed to treat/harm (NNT/NNH): A benefit/risk analysis of fruquintinib vs other treatments for metastatic colorectal cancer (mCRC)....\"",
      "stakeholders": {
        "count": 3,
        "locked": true,
        "preview": [
          "Tanios S. Bekaii-Saab",
          "Arvind Dasari",
          "Cathy Eng"
        ],
        "people": []
      }
    },
    {
      "rank": 28,
      "company": "National Cancer Institute",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"Indian Hedgehog expression and association with cetuximab benefit in metastatic colorectal cancer (mCRC): Evidence from CALGB (Alliance)/SWOG 80405....\"",
      "stakeholders": {
        "count": 3,
        "locked": true,
        "preview": [
          "Michela Bartolini",
          "Yan Yang",
          "Sandra Algaze"
        ],
        "people": []
      }
    },
    {
      "rank": 29,
      "company": "Bexion Pharmaceuticals",
      "domain": null,
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator,...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Tariq Arshad",
          "Michael Gazda"
        ],
        "people": []
      }
    },
    {
      "rank": 30,
      "company": "AbbVie Inc",
      "domain": "abbvie.com",
      "abstractCount": 2,
      "signalDetail": "2 sponsored abstracts at ASCO GI 2026 (2 poster). Lead: \"A phase 2 randomized study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with standard of care (SOC) in patients with metastatic colo...\"",
      "stakeholders": {
        "count": 4,
        "locked": true,
        "preview": [
          "Ardaman Shergill",
          "Michael Cecchini",
          "Kanwal P. Raghav"
        ],
        "people": []
      }
    },
    {
      "rank": 31,
      "company": "Shanghai Junshi Biosciences",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 oral). Lead: \"Perioperative PD-1 antibody toripalimab combined with chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction ...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Shu-Qiang Yuan",
          "Run-Cong Nie"
        ],
        "people": []
      }
    },
    {
      "rank": 32,
      "company": "Daiichi Sankyo",
      "domain": "daiichisankyo.com",
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo +...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Kohei Shitara",
          "Lin Shen"
        ],
        "people": []
      }
    },
    {
      "rank": 33,
      "company": "Astellas Pharma Inc",
      "domain": "astellas.com",
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Randomized phase II trial evaluating the efficacy of zolbetuximab in the second-line for claudin18.2 positive advanced gastric/EGJ cancer patients pre...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Koji Ando",
          "Chiaki Inagaki"
        ],
        "people": []
      }
    },
    {
      "rank": 34,
      "company": "Rakuten Medical",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Phase Ib/II study of ASP-1929 photoimmunotherapy (PIT) for esophageal cancer ineligible for curative standard therapies....\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Hironori Sunakawa",
          "Mitsuko Suzuki"
        ],
        "people": []
      }
    },
    {
      "rank": 35,
      "company": "Eli Lilly and Company",
      "domain": "lilly.com",
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in pa...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Matthew Hayes",
          "Takako E. Nakajima"
        ],
        "people": []
      }
    },
    {
      "rank": 36,
      "company": "MSD China",
      "domain": "merck.com",
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Real-world treatment patterns and biomarker testing landscape of locally advanced gastric/gastroesophageal junction cancer (LA GC/GEJC) in China (SURP...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Dan Su",
          "Chuanhua Zhao"
        ],
        "people": []
      }
    },
    {
      "rank": 37,
      "company": "Amgen",
      "domain": "amgen.com",
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Patient characteristics, first-line treatments, and overall survival among locally advanced, unresectable or metastatic gastric and gastroesophageal j...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Isadora Guimaraes Martins",
          "Stephanie R. Reading"
        ],
        "people": []
      }
    },
    {
      "rank": 38,
      "company": "Iksuda Therapeutics Limited",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Early analysis of activity in esophageal cancer during phase 1 dose escalation of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participa...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Malaka Ameratunga",
          "Adnan Nagrial"
        ],
        "people": []
      }
    },
    {
      "rank": 39,
      "company": "TAIHO Phamaceutical Co., Ltd.",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"The primary results of a randomized phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus FTD/TPI for previously treated pa...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Naoki Takahashi",
          "Hiroki Hara"
        ],
        "people": []
      }
    },
    {
      "rank": 40,
      "company": "HUTCHMED Pharmaceutical Company",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma....\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Nan An",
          "Jiaying Chen"
        ],
        "people": []
      }
    },
    {
      "rank": 41,
      "company": "BeOne Medicines Ltd",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"A phase 2 study of LBL-007 (anti-LAG-3) plus tislelizumab (anti-PD-1) and chemotherapy as first-line treatment in patients with unresectable locally a...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Yi Ba",
          "Jing Zhang"
        ],
        "people": []
      }
    },
    {
      "rank": 42,
      "company": "Legend Biotech",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Phase 1 study of LB1908, an autologous claudin 18.2-targeted CAR-T cell product, in subjects with advanced gastroesophageal adenocarcinoma....\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "David B. Zhen",
          "Richard T. Maziarz"
        ],
        "people": []
      }
    },
    {
      "rank": 43,
      "company": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Preliminary results of benmelstobart (BEN) combined with concurrent chemoradiotherapy (cCRT) versus cCRT alone as neoadjuvant therapy for esophageal s...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Han Tang",
          "Yang Zhang"
        ],
        "people": []
      }
    },
    {
      "rank": 44,
      "company": "BeOne Medicines Ltd.",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Modeling analysis of RATIONALE-305: Impact of peritoneal metastasis (PM) representation on clinical outcomes in patients (pts) treated with tislelizum...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Mohamad B. Sonbol",
          "Sun Young Rha"
        ],
        "people": []
      }
    },
    {
      "rank": 45,
      "company": "Funded by Boehringer Ingelheim",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"A phase I first in human, open-label, multicenter study of BI3706674, KRAS multi-inhibitor, monotherapy in patients with advanced solid tumors bearing...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Andreas Varkaris",
          "Yasutoshi Kuboki"
        ],
        "people": []
      }
    },
    {
      "rank": 46,
      "company": "BeOne Medicines, Ltd.",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT as first-line treatment for locally advanced (LA), unresectable esophageal squamous cell ...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Harry H. Yoon",
          "Sunnie S. Kim"
        ],
        "people": []
      }
    },
    {
      "rank": 47,
      "company": "Yakult Honsha Co., Ltd.",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Three-year and five-year outcomes of a phase II study of perioperative CapeOx therapy for advanced gastric cancer with extensive lymph node metastasis...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Ryohei Kawabata",
          "Yutaka Kimura"
        ],
        "people": []
      }
    },
    {
      "rank": 48,
      "company": "Taiho",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"ACCRU-GI-1810: Trifluridine/tipiracil (FTD-TPI) or paclitaxel (PAC) in combination with ramucirumab (RAM) for patients (pts) with previously treated a...\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Mohamad B. Sonbol",
          "Angela Ulrich"
        ],
        "people": []
      }
    },
    {
      "rank": 49,
      "company": "Janssen Pharmaceuticals",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"AMIGO: A phase 2 trial of amivantamab in <em>EGFR </em>or<em> MET-</em>amplified gastroesophageal adenocarcinoma (GEA)....\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Steven B. Maron",
          "Charlton Tsai"
        ],
        "people": []
      }
    },
    {
      "rank": 50,
      "company": "Suzhou Immunofoco Biotechnology Co., Ltd.",
      "domain": null,
      "abstractCount": 1,
      "signalDetail": "1 sponsored abstracts at ASCO GI 2026 (1 poster). Lead: \"Phase I trial of efficacy and safety of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, for gastroesophageal cancers....\"",
      "stakeholders": {
        "count": 2,
        "locked": true,
        "preview": [
          "Chao Li",
          "Tianhang Luo"
        ],
        "people": []
      }
    }
  ]
}